NATCO Pharma Limited (NSE: NATCOPHARM)

Market Cap	279.39B
Revenue (ttm)	43.49B
Net Income (ttm)	16.37B
Shares Out	179.11M
EPS (ttm)	91.37
PE Ratio	17.07
Forward PE	14.30
Dividend	5.50 (0.35%)
Ex-Dividend Date	Aug 23, 2024

Volume	538,822
Open	1,562.95
Previous Close	1,555.75
Day's Range	1,532.00 - 1,577.95
52-Week Range	724.20 - 1,598.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 8, 2024

About NATCO Pharma

NATCO Pharma Limited, a pharmaceutical company, engages in the developing, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. The company offers orthopedic products comprising bisphosph...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1981
• Employees: 3,946
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: NATCOPHARM

Financial Performance

In 2023, NATCO Pharma's revenue was 41.27 billion, an increase of 52.37% compared to the previous year's 27.09 billion. Earnings were 13.88 billion, an increase of 94.09%.